Viewing Study NCT07336732

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2026-03-26 @ 3:17 PM
Ignite Modification Date: 2026-06-11 @ 1:32 AM
Study NCT ID: NCT07336732
Status: RECRUITING
Last Update Posted: 2026-03-20
First Post: 2025-12-18
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
Sponsor: Avistone Biotechnology Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small-Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small-Cell Lung Cance View
None EGFR View
None PACC View
None L861Q View
None Lung Cancer View
None EGFR ex20ins View